Get the Daily Brief
Latest Biotech News
Noa Therapeutics Advances Chronic Inflammatory Disease Pipeline with NEA Grant
Toronto-based Noa Therapeutics, pioneering biased engagement of the aryl hydrocarbon receptor (AhR), secured a Catalyst Research Grant from the National Eczema Association to study its lead...
Single-Cell Sequencing Trial Targets Myelodysplastic Syndromes Diagnostic Improvement
Researchers at the Weizmann Institute of Science initiated the PERIBLOOD clinical trial, enrolling 1,500 patients globally to evaluate single-cell sequencing utility in diagnosing myelodysplastic...
Cancer Therapy Innovation: Antibody–Bottlebrush Prodrugs and Immune Checkpoint Inhibitors
Nature Biotechnology published advancements in targeted cancer therapies, including antibody–bottlebrush prodrugs that offer expanded payload flexibility and improved delivery over traditional...
AI-Powered Environmental and Biological Monitoring Expands Frontiers
Innovations in AI and sensing technologies are revolutionizing environmental and biological surveillance. Researchers developed a self-powered microfluidic sensor detecting toxic amines in water...
Novel Diagnostics and Biomarkers in Alzheimer’s and Cancer Care
UC San Diego researchers identified blood biomarkers linked to cognitive decline in Hispanic/Latino adults, paving the way for a simple test for early Alzheimer's detection. Additionally, spatial...
Novartis Bolsters Cardiovascular Pipeline with $1.4B Tourmaline Bio Buy
Novartis has agreed to acquire Tourmaline Bio for approximately $1.4 billion, securing exclusive rights to pacibekitug, a promising anti-IL-6 monoclonal antibody aimed at tackling atherosclerotic...
Rapport’s Anti-Seizure Drug Surges on Phase II Success
Rapport Therapeutics reported robust Phase IIa data for RAP-219, an experimental drug targeting TARPγ8-specific AMPA receptors, showing a 78% median reduction in clinical seizures in patients with...
New FDA Approval for Johnson & Johnson’s Bladder Cancer Treatment Inlexzo
Johnson & Johnson secured FDA approval for Inlexzo, an intravesical gemcitabine delivery system for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer...
Alzinova Advances Alzheimer’s Vaccine Candidate ALZ-101 to Phase II
Swedish biopharmaceutical company Alzinova received FDA clearance to begin Phase II clinical trials of ALZ-101, a vaccine targeting toxic amyloid-beta oligomers in Alzheimer’s disease. Following...
Eli Lilly Opens AI Drug Discovery Models to Biotech Partners via TuneLab
Eli Lilly launched TuneLab, an innovative AI platform providing early-stage biotech firms access to Lilly’s proprietary drug discovery machine learning models. Participating companies contribute...
Breakthrough Antibody–Bottlebrush Prodrugs Expand Cancer Therapeutics
Researchers unveiled antibody–bottlebrush prodrug conjugates that overcome payload potency and stability limitations of conventional antibody–drug conjugates (ADCs). This modular synthesis allows...
Imperial Scientists Uncover ‘Microbial Piracy’ Mechanism to Combat Drug Resistance
A team at Imperial College London discovered that phage satellites hijack tails from unrelated bacteriophages, forming hybrid viruses that facilitate genetic exchange among bacteria. This...
Medicus Pharma Acquires Antev, Tapping $6 Billion Prostate Cancer Market
Medicus Pharma completed acquisition of UK-based Antev Limited, gaining full rights to Teverelix, a GnRH antagonist targeting prostate cancer and acute urinary retention. Valued at an estimated $6...
NRG Therapeutics Raises $67 Million to Test Mitochondrial Treatments for ALS
NRG Therapeutics Ltd., focused on neuroscience, secured a £50 million (approximately $67 million) Series B funding to advance preclinical development of novel small molecules modulating the...
Novartis Accelerates Cardiovascular Pipeline with $1.4B Tourmaline Acquisition
Novartis has completed a $1.4 billion acquisition of Tourmaline Bio, securing rights to pacibekitug, an anti-IL-6 monoclonal antibody aimed at atherosclerotic cardiovascular disease (ASCVD)....
Rapport Therapeutics’ Seizure Drug RAP-219 Shakes Up Epilepsy Market
Rapport Therapeutics reported striking Phase IIa results for its focal onset seizure drug RAP-219, showing a 78% median reduction in clinical seizures over eight weeks. The open-label study,...
WCLC 2025: Emerging Small Cell Lung Cancer Therapies Reveal Mixed Outcomes
At the World Conference on Lung Cancer (WCLC) 2025, several investigational treatments for small cell lung cancer (SCLC) showed promising yet mixed clinical trial results. BioNTech and Bristol...
FDA Returns Complete Response Letter for Saol’s Rare Genetic Disorder Treatment
Saol Therapeutics received an FDA complete response letter (CRL) for its NDA on sodium dichloroacetate (SL-1009), an experimental drug for pyruvate dehydrogenase complex deficiency, a rare...
AI-Driven Drug Discovery Models Opened to Biotech Startups by Eli Lilly
Eli Lilly unveiled TuneLab, an AI platform granting early-stage biotechs access to proprietary drug discovery models developed using decades of Lilly’s research data. Participating companies...
Breakthrough Alzheimer’s Vaccine ALZ-101 Initiates Phase II Clinical Trial
Alzinova secured FDA approval to advance its novel Alzheimer’s vaccine candidate ALZ-101 into Phase II clinical testing in the United States. ALZ-101 is designed to stimulate antibodies targeting...